Inspyr Therapeutics, Inc. announced the appointments of David Maloney, and Matthew Boxer, as Vice Presidents and Co-heads of Translational Medicine. They join the company from the National Institutes of Health (NIH) to lead Inspyr's translational medicine function, focused on designing, implementing, and managing all aspects of lead asset Mipsagargin's preclinical studies, including new combination studies, as well as new asset development. Matthew Boxer most recently at NCATS, where he was Medicinal Chemistry Group Leader. David Maloney, Ph.D. joined Inspyr following a nine-year career at the NIH’s National Center for Advancing Translational Sciences (NCATS), where he was a Group Leader in Chemistry and co-led an interdisciplinary project team. Most recently, he co-led a multi-center, NCI-funded drug discovery effort targeting an enzyme involved in cancer metabolism. Matthew Boxer, Ph.D. joined Inspyr following a nine-year career at the NIH, most recently at NCATS, where he was Medicinal Chemistry Group Leader. Recently, Matthew was project lead on a multi-institutional drug discovery project targeting an enzyme frequently mutated in cancer, and delivered a compound ready for investigational new drug (IND)-enabling studies.